IRWD IRONWOOD PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, IRONWOOD PHARMACEUTICALS INC reported revenue of $113M (up 32.6% from a year earlier), net income of $51.3M and diluted EPS of $0.31; over the last four quarters revenue was $389M and net income $130M; for the fiscal year ended December 2025 revenue was $296M, down 15.7% on the year before.

IRWD annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $296M, gross profit n/a, operating income $98.5M, net income $24.0M (margin 8.1%), EPS $0.15
• Fiscal year ended Dec 2024: revenue $351M, gross profit n/a, operating income $93.1M, net income $880K (margin 0.3%), EPS $0.01
• Fiscal year ended Dec 2023: revenue $443M, gross profit n/a, operating income −$945M, net income −$1.03B (margin -233.0%), EPS −$6.45
• Fiscal year ended Dec 2022: revenue $411M, gross profit n/a, operating income $250M, net income $175M (margin 42.6%), EPS $0.96
• Fiscal year ended Dec 2021: revenue $414M, gross profit n/a, operating income $232M, net income $528M (margin 127.7%), EPS $3.21

IRWD quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $113M (up 32.6% year over year), net income $51.3M, EPS $0.31
• Quarter ended Mar 31, 2026: revenue $107M (up 158.9% year over year), net income $40.8M, EPS $0.24
• Quarter ended Dec 31, 2025: revenue $47.7M (down 47.3% year over year), net income −$2.28M, EPS −$0.01
• Quarter ended Sep 30, 2025: revenue $122M (up 33.3% year over year), net income $40.1M, EPS $0.23
• Quarter ended Jun 30, 2025: revenue $85.2M (down 9.7% year over year), net income $23.6M, EPS $0.14
• Quarter ended Mar 31, 2025: revenue $41.1M (down 45.1% year over year), net income −$37.4M, EPS −$0.23
• Quarter ended Dec 31, 2024: revenue $90.5M (down 23.0% year over year), net income $2.26M, EPS $0.01
• Quarter ended Sep 30, 2024: revenue $91.6M (down 19.5% year over year), net income $3.65M, EPS $0.02
• Quarter ended Jun 30, 2024: revenue $94.4M (down 12.1% year over year), net income −$860K, EPS −$0.01
• Quarter ended Mar 31, 2024: revenue $74.9M (down 28.0% year over year), net income −$4.16M, EPS −$0.03
• Quarter ended Dec 31, 2023: revenue $118M (up 9.7% year over year), net income −$1.09M, EPS −$0.01
• Quarter ended Sep 30, 2023: revenue $114M (up 4.7% year over year), net income $15.3M, EPS $0.09
• Quarter ended Jun 30, 2023: revenue $107M (up 10.4% year over year), net income −$1.06B, EPS −$6.84
• Quarter ended Mar 31, 2023: revenue $104M (up 6.7% year over year), net income $45.7M, EPS $0.25
• Quarter ended Dec 31, 2022: revenue $107M (down 8.5% year over year), net income $48.9M, EPS $0.27
• Quarter ended Sep 30, 2022: revenue $109M (up 4.7% year over year), net income $50.3M, EPS $0.28
• Quarter ended Jun 30, 2022: revenue $97.2M (down 6.5% year over year), net income $37.1M, EPS $0.21
• Quarter ended Mar 31, 2022: revenue $97.5M (up 9.8% year over year), net income $38.8M, EPS $0.21
• Quarter ended Dec 31, 2021: revenue $117M, net income $41.4M, EPS $0.25
• Quarter ended Sep 30, 2021: revenue $104M, net income $55.8M, EPS $0.34

IRWD cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $127M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $104M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $183M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $274M, share buybacks $126M
• Fiscal year ended Dec 2021: operating cash flow $262M, share buybacks $24.1M

IRWD balance sheet

• Jun 30, 2026: cash $79.1M, total assets $285M, total liabilities $447M, shareholders' equity −$162M
• Mar 31, 2026: cash $220M, total assets $435M, total liabilities n/a, shareholders' equity −$217M
• Dec 31, 2025: cash $215M, total assets $397M, total liabilities $659M, shareholders' equity −$262M
• Sep 30, 2025: cash $140M, total assets $396M, total liabilities n/a, shareholders' equity −$264M
• Jun 30, 2025: cash $92.9M, total assets $343M, total liabilities n/a, shareholders' equity −$308M
• Mar 31, 2025: cash $108M, total assets $327M, total liabilities n/a, shareholders' equity −$334M
• Dec 31, 2024: cash $88.6M, total assets $351M, total liabilities n/a, shareholders' equity −$301M
• Sep 30, 2024: cash $88.2M, total assets $390M, total liabilities n/a, shareholders' equity −$311M

What is IRWD's revenue?

IRONWOOD PHARMACEUTICALS INC reported $389M of revenue over its last four quarters, through June 30, 2026.

Is IRWD profitable?

Yes. IRONWOOD PHARMACEUTICALS INC earned $130M over the last four quarters.

What is IRWD's EPS?

Diluted earnings per share over the last four quarters were $0.77; $0.31 in the latest quarter.

IRWD ownership and insider trades · All stocks